Darunavir Ethanolate CAS 635728-49-3 Maʻemaʻe ≥99.0% API Factory Anti-HIV HIV Protease Inhibitor
Hāʻawi ka mea hana iā Darunavir i nā huahana pili:
Darunavir CAS 206361-99-1
Darunavir Ethanolate CAS 635728-49-3
(2S,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane CAS 98737-29-2
(2R,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane CAS 98760-08-8
(3S)-3-(tert-Butoxycarbonyl)amino-1-Chloro-4-Phenyl-2-Butanone CAS 102123-74-0
| Inoa Kimia | ʻO Darunavir Ethanolate |
| Nā huaʻōlelo like | DRV;Prezista;TMC114 Ethanolate;UNII-33O78XF0BW;N-[(1S,2R)-3-[[(4-Aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamic acid (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl ester compd.me ka ethanol |
| Helu CAS | 635728-49-3 |
| Helu CAT | RF-API69 |
| Kūlana Kūʻai | Ma ka waihona, ʻoi aku ka nui o ka hana a hiki i nā haneli kilogram |
| ʻĀpana Molekala | C29H43N3O8S |
| Kaumaha Molecular | 593.73 |
| Brand | Kemika Ruifu |
| 'ikamu | Nā kikoʻī |
| Ka nana aku | Keʻokeʻo a i ʻole ke keʻokeʻo Crystalline pauda |
| ʻIkepili IR | Kūlike me ka Spectrum maʻamau |
| Hoʻololi kikoʻī | -0.5°~ +0.5° |
| Na mea pili | (na HPLC) |
| Max Hoʻokahi haumia | ≤0.20% |
| Huina paumaele | ≤0.50% |
| Wai (KF) | ≤1.0% |
| Koena ma ka Ignition | ≤0.10% |
| Nā Metala Kaumaha | ≤10ppm |
| Maʻiʻo o ka Ethanol | ≤7.5% (GC) |
| Nā mea hoʻoheheʻe koena | Methanol ≤0.30% |
| Maemae | ≥99.0% (HPLC) |
| Kūlana hoʻāʻo | Kūlana ʻoihana |
| Hoʻohana | ʻO Darunavir Ethanolate HIV-1 Protease Inhibitor Anti-HIV Antiviral |
Pūʻolo: ʻO ka ʻōmole, ʻeke ʻeke alumini, pahu pahu pahu, 25kg / pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;Palekana mai ka malamalama, ka ma'ū a me ka pest infestation.
ʻO Darunavir Ethanolate (Prezista) kahi mea hoʻopaneʻe protease HIV.Derivative o Darunavir, ka lua o ka hanauna HIV-1-protease inhibitor;e like me ka amprenavir.Antiviral.He huahana noiʻi pili COVID19.ʻO ka mea pōʻino, he haʻahaʻa ko DRV i ka wai a me ka bioavailability maikaʻi ʻole, no laila pono ia i ka hoʻokele ʻana i nā koina kiʻekiʻe i mea e hōʻike ai i ka hopena therapeutic.ʻO Darunavir kahi mea hoʻokae ākea ākea e kūʻē i nā maʻi maʻi HIV-1 me ka liʻiliʻi o ka cytotoxicity.Hoʻokumu ʻo Darunavir i nā paʻa hydrogen me nā ʻātoma kaulahao nui i mālama ʻia o Asp29 a me Asp30 o ka protease.Manaʻo ʻia kēia mau pilina i mea koʻikoʻi no ka ikaika o kēia pūhui e kūʻē i nā mea hoʻokaʻawale HIV i kū kūʻē i nā mea paʻa protease lehulehu.Ma kahi haʻawina in vitro i loko o nā cell MT-2, ʻoi aku ka ikaika o ka darunavir ma mua o ka saquinavir, amprenavir, nelfinavir, indinavir, lopinavir a me ritonavir.Hoʻopili mua ʻia ʻo Darunavir e nā enzymes cytochrome P450 (CYP) hepatic, ʻo CYP3A.ʻO ka 'boosting' dose o ritonavir e hana i kahi inhibitor o CYP3A, e hoʻonui ai i ka bioavailability darunavir.Ua hoʻolālā ʻia ʻo Darunavir e hana i nā pilina paʻa me ka enzyme protease mai nā maʻi he nui o ka maʻi HIV, e komo pū ana me nā maʻi mai nā maʻi i hoʻomaʻamaʻa ʻia me nā mutati kūʻē he nui.
